Century Therapeutics (IPSC)
Develops iPSC-derived allogeneic cell therapies for autoimmune disease and cancer.
Something off on this page? Send us feedback.
Develops off-the-shelf, iPSC-derived cell therapies for autoimmune disease, including type 1 diabetes, and cancer. Its development pipeline includes beta-islet, alpha-beta immune T-cell, and CAR-iNK programs.
Develops off-the-shelf, iPSC-derived allogeneic cell therapies for autoimmune disease, including type 1 diabetes, and cancer. The platform combines induced pluripotent stem cells with gene editing, protein engineering, technical development, and manufacturing.
Current programs include CNTY-813, a beta-islet-cell program for type 1 diabetes; CNTY-308, a CD19-targeted alpha-beta immune T-cell program for B-cell-mediated autoimmune diseases; and CNTY-101, a CD19 CAR-iNK program in an investigator-sponsored trial. These are development programs, not approved commercial products.
Operates as a research-and-development biotechnology business with one reportable segment. The business depends on clinical progress, manufacturing, licensing and collaboration arrangements, and financing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Mar 13, 2026 | Leerink Partners | Target | Target: $27 | Target: $2 |
| Jan 20, 2026 | Piper Sandler | Reiterate | Rating: —Target: $9 | Target: $4 |
| Nov 17, 2025 | Leerink Partners | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $119.7M · Total debt $34.6M · Total assets $287.0M · Shareholders' equity $232.3M
- Revenue
- $0
- Operating income
- −$36.5M
- Net income
- −$34.6M
No dividends on record.
| Institutions | ≈ 87.47% | 158.38M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.40% | 6.16M shares | |
| 6 holders · as of Sep 15, 2026 | |||
| Other | ≈ 9.13% | 16.53M shares | |
| remainder | |||
181.08M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (181.08M in the company's Sep 23, 2026 report, 86.57M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 9.80% | 17.75M | as of Jun 30, 2026 |
TCG Crossover Management, LLCInstitution | 9.80% | 17.75M | as of Jun 30, 2026 |
Venrock Healthcare Capital Partners III, L.P.Institution | 7.20% | 13.04M | filed Jan 16, 2026 |
Versant Venture Management, LLCInstitution | 6.72% | 12.17M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 5.23% | 9.46M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Douglas Carr | officer: SVP Finance & Operations | −1,658 | $1.93 |
| Sep 14, 2026 | Gregory Russotti | officer: See Remarks | −2,587 | $1.93 |
| Sep 8, 2026 | Douglas Carr | officer: SVP Finance & Operations | −254 | $2.05 |
| Sep 8, 2026 | Gregory Russotti | officer: See Remarks | −534 | $2.05 |
| Aug 3, 2026 | Douglas Carr | officer: SVP Finance & Operations | −275 | $1.98 |
- Vertex Pharmaceuticals
Stem-cell-derived islet replacement for type 1 diabetes
- Sana Biotechnology
Hypoimmune iPSC-derived islet therapy for type 1 diabetes
- CRISPR Therapeutics
Gene-edited allogeneic cell programs in diabetes and autoimmunity
- Allogene Therapeutics
Dual-targeted allogeneic CAR-T for B-cell autoimmune disease
- Fate
iPSC-derived off-the-shelf CD19 CAR-T and CAR-NK programs
- Nkarta
Allogeneic CD19 CAR-NK therapy for B-cell autoimmune diseases
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Century Therapeutics | $1.81 | −4.23% | $163.6M | — | — | — | — |
| Vertex Pharmaceuticals | $510.86 | −0.80% | $130.71B | 30.0 | 26.6 | 10.4 | +12.5% |
| Sana Biotechnology | $3.11 | −6.76% | $926.7M | — | — | — | — |
| CRISPR Therapeutics | $56.42 | −4.42% | $5.69B | — | — | 425.1 | +1,041.4% |
| Allogene Therapeutics | $1.67 | −2.61% | $590.2M | — | — | 127.2 | — |
| Fate | $2.46 | −4.84% | $300.7M | — | — | 46.3 | +9.2% |
| Nkarta | $2.68 | −9.21% | $211.1M | — | — | — | — |
| Median | 30.0 | 26.6 | 86.8 | +12.5% |